ClinicalTrials.gg
TerminatedNCT05424562LIVENUpdated Sep 29, 2026

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Terminated at 20 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by AbbVie · Observational

How we know

Why this study was terminated
Strategic Considerations
Updated Sep 29, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.

Enrollment
2nd of 10
210 · median 113
Started
2022
with 2 others
Observational
10 of 43
1 open now
Registered
35th of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 2nd largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 35th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by AbbVie, or all of them as a file.
02

Study summary

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult participants who are ineligible for intensive induction chemotherapy in Canada.

Venetoclax is a drug approved to treat Acute Myeloid Leukemia (AML). All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive induction chemotherapy will be enrolled. Around 200 participants will be enrolled in the study in approximately 15-20 sites in Canada.

Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 36 months.

There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 36 months.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Venetoclax
  • Venclexta
  • Venclyxto
  • ABT-199
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with acute myeloid leukemia (AML) treated with venetoclax per approved local label in Canada.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Acute Myeloid Leukemia (AML).
  • Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice.
  • Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study.

Exclusion criteria

Exclusion Criteria:

- Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (actual)

Groups and cohorts

  • Venetoclax Participants

    Participants treated with Venetoclax in accordance with approved local label.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS as defined by number of days from start of treatment to the completion of treatment or death from any cause.

    Time frame: Up to 36 Months

Secondary outcomes

  1. Change in Composite Complete Remission Rate

    Composite Complete Remission Rate is defined as complete remission (CR) plus complete remission with incomplete hematologic recovery (CRi) as described by the modified International Working Group (IWG) criteria.

    Time frame: Up to 36 Months

  2. Event-Free Survival (EFS)

    EFS as defined by number of days from start of treatment to the date of progressive disease, relapse from CR or CRi, treatment failure or death from any cause.

    Time frame: Up to 36 Months

  3. Percentage of Participants with Presence Transfusion Independence

    Transfusion Independence is defined as at least 8 and/or 16 consecutive weeks without an Red Blood Cell (RBC) or platelet transfusion during the treatment period.

    Time frame: Up to 36 Months

  4. Number of Participants with Transfusions

    Number of Participants with transfusions (red blood cells and platelets).

    Time frame: Up to 36 Months

  5. Number of Participants with Change in Venetoclax Dose

    Number of participants with change in venetoclax dose.

    Time frame: Up to 36 Months

  6. Number of Participants with Change in Other Medications

    Number of participants with change in other medications.

    Time frame: Up to 36 Months

  7. Venetoclax Administration Setting

    Venetoclax administration setting (in-patient vs. out-patient vs. at home).

    Time frame: Up to 36 Months

  8. Number of Hospital Admission

    Number of hospital admission.

    Time frame: Up to 36 Months

  9. Number of Participants with Change in use of Antiinfectives

    Number of participants with change in use of antiinfectives.

    Time frame: Up to 36 Months

  10. Number of Participants with Change in Tumor Lysis Syndrome (TLS) Risk

    Number of participants with change in TLS risk.

    Time frame: Up to 36 Months

  11. Occurrence of any Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).

    Time frame: Up to 36 Months

07

Study locations

20 sites
  • Tom Baker Cancer Centre /ID# 248113
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Hospital /ID# 251531
    Edmonton, Alberta T6G 2B7, Canada
  • BC Cancer - Surrey /ID# 257515
    Surrey, British Columbia V3V 1Z2, Canada
  • Vancouver General Hospital /ID# 245438
    Vancouver, British Columbia V5Z 1M9, Canada
  • BC Cancer - Victoria /ID# 257339
    Victoria, British Columbia V8R 6V5, Canada
  • CancerCare Manitoba /ID# 246414
    Winnipeg, Manitoba R3E 0V9, Canada
  • The Moncton Hospital /ID# 247277
    Moncton, New Brunswick E1C 6Z8, Canada
  • Eastern Regional Health Authority /ID# 250241
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 246514
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Juravinski Cancer Centre /ID# 247183
    Hamilton, Ontario L8V 1C3, Canada
  • Kingston Health Sciences Centre /ID# 253439
    Kingston, Ontario K7L 2V7, Canada
  • London Health Sciences Center- University Hospital /ID# 248027
    London, Ontario N6A 5W9, Canada
  • Lakeridge Health - Oshawa /ID# 246412
    Oshawa, Ontario L1G 2B9, Canada
  • Thunder Bay Regional Research Institute /ID# 249163
    Thunder Bay, Ontario P7B 6V4, Canada
  • Sunnybrook Health Sciences Centre /ID# 251966
    Toronto, Ontario M4N 3M5, Canada
  • University Health Network_Princess Margaret Cancer Centre /ID# 249607
    Toronto, Ontario M5G 2M9, Canada
  • Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 249704
    Montreal, Quebec H4A 3J1, Canada
  • CIUSSS de l'Estrie - CHUS /ID# 248915
    Sherbrooke, Quebec J1G 2E8, Canada
  • Allan Blair Cancer Centre /ID# 247663
    Regina, Saskatchewan S4T 7T1, Canada
  • Saskatoon Cancer Centre /ID# 247181
    Saskatoon, Saskatchewan S7N 4H4, Canada
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2022 to primary completion in Aug 2026, 47 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Mar 2027 → Aug 2026 and completion Mar 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2022
First posted
Jun 21, 2022
StartActual
Sep 7, 2022
Primary completionActual
Aug 31, 2026was Mar 2027
CompletionActual
Aug 31, 2026was Mar 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Strategic Considerations
changed Sep 29, 2026
Primary completion
Mar 2027→Aug 31, 2026 (actual)
Sep 29, 2026
Study completion
Mar 2027→Aug 31, 2026 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Terminated
    Why stopped Strategic Considerations
    Primary completion Mar 2027→Aug 31, 2026 (now actual)
    Study completion Mar 2027→Aug 31, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05424562
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Sep 7, 2022
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Sep 29, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion